It works! PEAQX (NVP-AAM 077) blocks a considerable portion of the NMDA-mediated current in whole cell patch set-up. Verified customer, Rutgers University
Potent and competitive NMDA receptor antagonist. Binds at the glutamate site.
Shows some selectivity (~7-10-fold) for GluN1/2A (NR1/2A) over GluN1/2B (NR1/2B) subunit containing receptors (IC50 values are 31 and 215 nM at GluN1/2A and GluN1/2B respectively).
Shows anticonvulsant activity. Active in vivo.
Solubility & Handling
Storage instructions
-20°C
Solubility overview
Soluble in water (10mM)
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.
References are publications that support the biological activity of the product
The effects of an acute challenge with the NMDA receptor antagonists, MK-801, PEAQX, and ifenprodil, on social inhibition in adolescent and adult male rats.
Morales and Spear (2014) Psychopharmacology (Berl). 231(8) : 1797-807
Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B NMDA receptors: Implications for studies of sy
Frizelle et al (2006) Mol Pharmacol. 70(3) : 1022-32
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.
Auberson et al (2002) Bioorg Med Chem Lett 12(7) : 1099-102.
These publications cite the use of PEAQX (NVP-AAM 077) purchased from Hello Bio:
Cellular and Molecular Changes in Hippocampal Glutamate Signaling and Alterations in Learning, Attention, and Impulsivity Following Prenatal Nicotine Exposure
Polli et al. (2020) Mol Neurobiol 57(4) : 2002-2020